What I keep saying is praising "positive trending interim data" not even Topline data or Final data is fools gold. What I'm not saying is hold up a Chronic Cough standalone clinical trial that should have happened in the first place. If you wanna tout positive data it should be the data they got from Chronic Cough in the preclinical trial where Ifenprodil outperformed Merck's Phase 3 drug by 110%. That was the move to make from a cost effective and expedient result that could potentially propel Algernon Pharmaceuticals beyond the dumpster fire Team Cobra biotech it's widely known for. You can't tell me it would have taken this long to get 'positive trending interim data" for 14 frigging people (70% of 20 people) in a standalone study. So management believing that data is now enough to move forward with a real clinical trial begs the question of why go after harder to treat IPF patients versus Chronic Cough patients they now intend to target the same as Bellus Health. IMO, the logic in that initial decision was rife for further dilution then and now.
The "positive trending interim data" from the AU/NZ study...when can we see it? Will we ever? Or, will it simply be absorbed as such and we'll get Topline/Final data sometime maybe in 2022. I continue to question shareholders willingness to bend over and take it. But hey, it's your world. You run it the way you see fit.
Meanwhile...I still have no idea what you mean by this:
tcm55 - Thanks for the past support from the 5...
tcm55 - Maybe LS* can do a PP until we get a BP partner's/sponsor's $$$.
Care to further elaborate?
M$
News 
Market Data 
Discover 
